Cabozantinib is from which manufacturer?

Cabozantinib (Cabozantinib), sold under the brand names Cometriq and Cabometyx, is an anticancer drug used to treat medullary thyroid cancer, renal cell carcinoma and hepatocellular carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2 and also inhibits AXL and RET. Cabozantinib was discovered and developed by Exelixis. The U.S. Food and Drug Administration (FDA) approved cabozantinib capsule formulations under the name Cometriq for the treatment of patients with medullary thyroid cancer, and the FDA approved cabozantinib tablets as a second-line treatment for kidney cancer, marketed under the name Cabometyx. The two brands, Cometriq and Cabometyx, have different formulas and are not interchangeable.